Analysis of the outcome of concurrent neoadjuvant chemoradiotherapy with S-1 compared to super-selective intra-arterial infusion for oral squamous cell carcinoma

Miyawaki,Akihiko; Hijioka,Hiroshi; Ikeda,Ryuji; Ishida,Takayuki; Nozoe,Etsuro; Nakamura,Norifumi

doi:10.3892/ol.2012.606

Analysis of the outcome of concurrent neoadjuvant chemoradiotherapy with S-1 compared to super-selective intra-arterial infusion for oral squamous cell carcinoma

Authors:
- Akihiko Miyawaki
- Hiroshi Hijioka
- Ryuji Ikeda
- Takayuki Ishida
- Etsuro Nozoe
- Norifumi Nakamura
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Field of Oral and Maxillofacial Rehabilitation, Advanced Therapeutics Course, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan, Department of Clinical Pharmacy and Pharmacology, Kagoshima University, Kagoshima 890-8544, Japan
Published online on: February 13, 2012 https://doi.org/10.3892/ol.2012.606
Pages: 995-1001

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We introduced concurrent neoadjuvant chemoradiotherapy (CCRT) with S-1, an oral fluoropyrimidine, as treatment for oral squamous cell carcinoma (OSCC) from October 2005. The clinical usefulness and medical safety of CCRT with S-1 (S-1 group) for OSCC were analyzed and compared with CCRT using super-selective intra-arterial infusion (AI group). The subjects in the S-1 group underwent external irradiation, at a total dose of 30 Gy, with S-1 chemotherapy. The AI group received cisplatin (CDDP) or carboplatin (CBDCA) combined with daily radiotherapy at a total dose of 40 Gy. The histological effects and disease-specific survival rates were almost equivalent in the S-1 and AI groups. Adverse events were less frequent in the S-1 group, while hematological toxicity, including anemia, thrombopenia and pharyngeal edema, was observed in the AI group. The results of this study indicate that CCRT combined with S-1 is a more effective and safer treatment for OSCC than AI.

View Figures

View References

1	Shirasaka T: Development history and concept of an oral anticancer agent S-1(TS-1^®): its clinical usefulness and future vistas. Jpn J Clin Oncol. 39:2–15. 2009. View Article : Google Scholar : PubMed/NCBI
2	Fuwa N: Current and future state of chemoradiotherapy for head and neck cancer. Nihon Igaku Hoshasen Gakkai Zasshi. 62:65–72. 2002.(In Japanese).
3	Choong N and Vokes E: Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin. 58:32–58. 2008. View Article : Google Scholar : PubMed/NCBI
4	Bernier J, Domenge C, Ozsahlin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 350:1945–1952. 2004. View Article : Google Scholar : PubMed/NCBI
5	Klug C, Berzaczy D, Voracek M, et al: Preoperative chemoradiotherapy in the management of oral cancer: A review. J Craniomaxillofac Surg. 36:75–88. 2008. View Article : Google Scholar : PubMed/NCBI
6	Yoshizaki T, Tanaka F, Shiga H, et al: Superselective intra-arterial chemotherapy for head and neck squamous cell carcinoma. Head and Neck Cancer. 29:445–449. 2003. View Article : Google Scholar
7	Shiga K, Yokoyama J, Tateda M, et al: Superselective intraarterial chemotherapy for patients with head and neck tumor. Head and Neck Cancer. 29:457–462. 2003. View Article : Google Scholar
8	Imai S, Gyoten M, Kajihara Y, et al: Superselective intraarterial chemotherapy using cisplatin(CDDP)-carboplatin(CBDCA) combined with radiotherapy for head and neck cancer. Head and Neck Cancer. 29:463–467. 2003. View Article : Google Scholar
9	Endo S, Suzuki S, Tsuji K, et al: Intraarterial concomitant chemoradiation for tongue cancer: analysis of 20 patients. Nippon Jibiinkoka Gakkai Kaiho. 108:689–693. 2005.(In Japanese).
10	Tohnai I: Intra-arterial chemotherapy for head and neck cancer. Gan To Kagaku Ryoho. 32:2024–2029. 2005.(In Japanese).
11	Tonai I, Mitsudo K, Nishiguchi H, et al: Daily concurrent chemoradiotherapy using superselective intra-arterial infusion via superficial temporal artery-preoperative therapy for stage III, IV oral cancer. Head and Neck Cancer. 31:413–418. 2005.
12	Mitsudo K, Shigetomi T, Fukui T, et al: Daily concurrent chemoradiotherapy with docetaxel (DOC) and cisplatin (CDDP) using superselective intra-arterial infusion via superficial temporal artery for advanced oral cancer. J Clin Oncol. abse170202009.
13	Harada K, Kawashima Y, Uchida D, et al: A case of advanced oral squamous cell carcinoma responding to concurrent radiotherapy. Gan To Kagaku Ryoho. 34:745–747. 2007.(In Japanese).
14	Tsukuda M, Kida A, Fujii M, et al: Long-term results of S-1 administration as adjuvant chemotherapy for advanced head and neck cancer. Gan To Kagaku Ryoho. 34:1215–1225. 2007.(In Japanese).
15	Shirasaki T, Maruya S, Namba A, et al: Treatment results of chemotherapy with S-1 for head and neck cancer. Gan To Kagaku Ryoho. 36:237–240. 2009.(In Japanese).
16	Matsui R, Mukai H, Imamura H, et al: Clinical evaluation of anti-tumor effect in concurrent radiotherapy with TS-1 for oral cancer (abstract). Jpn J Oral Maxillofac Surg. 55:572009.
17	Ohnishi K, Shioyama Y, Nakamura K, et al: Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer. J Radiat Res. 52:47–53. 2011. View Article : Google Scholar : PubMed/NCBI
18	Budach W, Hehr T, Budach V, et al: A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresectable locally advanced squamous cell head and neck cancer. BMC Cancer. 6:282006. View Article : Google Scholar
19	Shimosato Y, Oboshi S and Baba K: Histological evaluation of effects of radiotherapy and chemotherapy for carcinoma. Jpn J Clin Oncol. 1:19–35. 1971.
20	Böheim K and Spoendkin H: The effect of chemotherapy in relation to pathohistological tumor grading in head and neck cancer. Acta Otorhinolaryngol. 238:197–204. 1983.PubMed/NCBI
21	Kishimoto K, Yoshida S, Domaem S, et al: Concurrent chemoradiotherapy with TS-1 for advanced oral cancer-Feasibility, problems, and countermeasures for elderly patients with complication. Jpn J Oral Maxillofac Surg. 55:177–183. 2009.(In Japanese).
22	Zeng L, Ou G, Itasaka S, et al: TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci. 99:2327–2335. 2008. View Article : Google Scholar : PubMed/NCBI
23	Kirita T, Ohgi K, Kawakami M, et al: Primary tumor resection of tongue carcinoma based on response to preoperative therapy. Int J Oral Maxillofac Surg. 31:267–272. 2002. View Article : Google Scholar : PubMed/NCBI
24	Kuratomi Y, Satoh S, Monji M, et al: A comparative study of concurrent chemoradiotherapy with S-1 or CDDP for pharyngeal or laryngeal cancer. Gan To Kagaku Ryoho. 37:1471–1476. 2010.(In Japanese).
25	Yamamo N, Ohshima T, Sato T, et al: A case of interstitial pneumonia after S-1 administration for gastric cancer. Gan To Kagaku Ryoho. 35:1935–1937. 2008.(In Japanese).
26	Furutani K, Fuwa N, Kodaira T, et al: Combination therapy of continuous intra-arterial chemotherapy and radiotherapy for stage III, IV tongue cancer. Head and Neck Cancer. 37:419–423. 2005.